TABLE 7.
Summary of cefmetazole or meropenem dosing in patients with invasive urinary tract infection due to ESBL-producing E. coli a
| CMZ (n = 81) | MEM (n = 46) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CrCl (mL/min) category | n (%) | Dose (g) | Interval (h) | No. | MIC, median (range) | TAM for each regimen, median (IQR) | Clinically ineffective (early), no. | CrCl (mL/min) category | n (%) | Dose (g) | Interval (hour) | No. | Clinically ineffective (early), no. |
| <10 | 3 (3.7%) | 0.5 | 12 | 1 | <1 | 100 | 1 | <10 | 5 (11%) | 0.5 | 24 | 4 | |
| 1 | 24 | 1 | 4 | 99.8 | 1 | 24 | 1 | ||||||
| 2 | 24 | 1 | <1 | 100 | 10–25 | 16 (35%) | 1 | 12 | 6 | 1 | |||
| 10–29 | 20 (24.7%) | 1 | 12 | 11 | <1 (<1–4) | 100 (100–100) |
0.5 | 12 | 5 | ||||
| 1 | 24 | 5 b | NA (<1–4) | 80.9 (64.7–96) |
1 | 8 | 2 | ||||||
| 2 | 12 | 3 | 2 (<1–8) | 100 (100–100) |
1 | 0.5 | 8 | 1 | |||||
| 2 | 24 | 1 | 2 | 82.9 | 0.5 | 24 | 1 | ||||||
| 30–50 | 29 (35.8%) | 1 | 8 | 8 | <1 (<1–2) | 100 (100–100) |
4 | 0.25 | 12 | 1 | |||
| 1 | 12 | 9 | <1 (<1–4) | 100 (84.6–100) |
26–50 | 11 (24%) | 1 | 12 | 6 | 2 | |||
| 1 | 24 | 5 | <1 (<1–2) | 65 (55.6–90.2) |
1 | 8 | 2 | 1 | |||||
| 2 | 12 | 1 | 2 | 100 | 0.5 | 12 | 2 | ||||||
| 2 | 24 | 6 | <1 (<1–8) | 58.5 (43.0–62.6) |
2 | 12 | 1 | ||||||
| >50 | 29 (35.8%) | 1 | 6 | 2 | <1 (<1–<1) | 100 (100–100) |
>50 | 14 (30%) | 1 | 8 | 9 | 2 | |
| 1 | 8 | 10 b | <1 (<1–2) | 50 | 0.5 | 12 | 2 b | 2 | |||||
| 1 | 12 | 11 | <1 (<1–8) | 57.8 (41.5–82.4) |
0.5 | 6 | 1 | ||||||
| 2 | 12 | 4 | <1 (<1–<1) | 95.2 (89.6–100) |
0.5 | 8 | 1 | ||||||
| 2 | 24 | 2 | NA (2–8) | 43.6 (32.8–NA) | 1 | 12 | 1 | ||||||
a
Abbreviations. NA, not available; TAM, time above MIC.
b
For one case per each category, TAM could not be calculated; two isolates were missing from microbiological analyses at the central laboratory. One isolate was not identified as ESBL-producing E. coli in the central laboratory analysis, and thus excluded from the analysis (ESBL production of the E. coli isolate was reported in the hospital microbiological laboratory, with resistance to cefotaxime).